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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that slowly destroys 
memory and thinking skills, resulting in behavioral changes. It is estimated that nearly 36 
million are affected globally with numbers reaching 115 million by 2050. AD can only be 
definitively diagnosed at autopsy since its manifestations of senile plaques and neuro-
fibrillary tangles throughout the brain cannot yet be fully captured with current imaging 
technologies. Current AD therapeutics have also been suboptimal. Besides identifying 
markers that distinguish AD from controls, there has been a recent drive to identify 
better biomarkers that can predict the rates of cognitive decline and neocortical amyloid 
burden in those who exhibit preclinical, prodromal, or clinical AD. This review covers 
biomarkers of three main types: genes, cerebrospinal fluid-derived, and blood-derived 
biomarkers. Looking ahead, cutting-edge OMICs technologies, including proteomics 
and metabolomics, ought to be fully tapped in order to mine even better biomarkers for 
AD that are more predictive.
Keywords: Alzheimer’s disease, early detection, genetic biomarkers, neurochemical biomarkers, blood-derived 
biomarkers, longitudinal studies
Abbreviations: AAO, age at symptom onset; Aβ42, amyloid-beta1-42 peptide; ACs, acylcarnitines; AD, Alzheimer’s disease; 
ADAD, autosomal-dominant for AD; A1AT, alpha-1 antitrypsin; aMCI, amnestic mild cognitive impairment; AβPP, amyloid-β 
precursor protein; APOE/ApoE, apolipoprotein E; BACE1, β-site amyloid precursor protein cleaving enzyme; BBB, blood–brain 
barrier; BIN1, bridging integrator 1; BDNF, brain-derived neurotrophic factor; CDR-SB, clinical dementia rating sum of boxes; 
CLU, clusterin; Converterspre, phenoconverters prior to conversion; CNS, central nervous system; CP, ceruloplasmin; CFH, 
complement factor H; CR1, complement receptor 1; CSF, cerebrospinal fluid; DIAN, dominantly inherited Alzheimer network; 
DLB, dementia with Lewy bodies; EAO, estimated age at symptom onset; EOAD, early onset Alzheimer’s disease; EYOs, esti-
mated number of years to symptom onset; FGG, fibrinogen γ-chain; FTD, frontotemporal dementia. GRS; Genetic Risk Score; 
GWAS, genome-wide association studies; HC, healthy control; HuGENet, human genome epidemiology network; LOAD, late 
onset Alzheimer’s disease; naMCI, non-amnestic mild cognitive impairment; MMSE, mini-mental state examination; MCs, 
mutation carriers; NAND, non-AD neurodegenerative dementias; NFTs, neurofibrillary tangles; NGRN, neurogranin; NSE, 
neuron-specific enolase; NGS, next-generation sequencing; NCs, non-carriers; OR, odds ratio; PICALM, phosphatidylinositol 
clathrin assembly lymphoid-myeloid; PAGE, polyacrylamide gel electrophoresis; p-tau, phosphorylated tau; PAI, plasminogen 
activator inhibitor; PAM, predictive analysis of microarrays; PEDF, pigment epithelium-derived factor; PET, positive emis-
sion tomography; PC, phosphatidylcholine; PDD, Parkinson’s disease dementia; PPV/NPV, positive predictive value/negative 
predictive value; PSEN, presenilin; SAP, serum amyloid P-component precursor; SUVR, standardized uptake value ratio; SVM, 
support vector machine; TREM2, triggering receptor expressed on myeloid cells 2; T-Tau, total tau; VAD, vascular dementia; 
VCAM, vascular adhesion molecule; VILIP, visinin-like-protein; 2-DGE, 2-D gel electrophoresis.
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iNTRODUCTiON
Alzheimer’s disease (AD) is a progressive neurodegenerative dis-
order that slowly destroys memory and thinking skills, resulting in 
behavioral changes. This places an emotional toll on the patients’ 
caretakers, while placing a financial burden of approximately $214 
billion in 2014 alone on the American society (1). The number 
of those affected is expected to reach 115 million worldwide by 
2050. Thus, there is an ever-growing need to find biomarkers for 
the early diagnosis of AD as well as to predict disease progression. 
AD is defined by the presence of senile plaques and neurofibrillary 
tangles (NFTs) throughout the brain resulting in its shrinkage. 
Definitive AD pathology can only be determined at autopsy since 
these neurologic manifestations are not readily perceptible using 
current diagnostic technologies, making early diagnosis difficult 
and inaccurate (1, 2). Current scientific evidence suggests that 
in preclinical Alzheimer’s, brain changes caused by the disease 
may begin years before symptoms of mild cognitive impairment 
(MCI) set in Ref. (3). Also, current therapeutic approaches have 
been largely inadequate toward addressing the earliest clinical 
symptoms of AD, where neurological damage is irreversible (4). 
Thus, comprehensive research is being performed to identify bet-
ter biomarkers for the early detection of AD with the hope that an 
effective therapeutic window will emerge.
As Alzheimer’s research has progressed, two clinically 
accepted validated biomarkers, amyloid-β (Aβ) accumulation in 
cerebrospinal fluid (CSF) and Pittsburgh compound B positron 
emission tomography (PiB-PET) measurements, have changed 
the primary focus of biomarker research from differentiation 
between cognitively normal healthy controls (HC) and AD, to 
the ability of potential biomarkers to predict the rates of cognitive 
decline in those who exhibit preclinical, prodromal, or clinical 
AD (3, 5–8). Previous review articles have shed light on potential 
biomarkers meeting some of these criteria including imaging and 
animal studies (9–14). In contrast to those reviews, the present 
article will focus on updating our current understanding of AD 
biomarkers harnessed from the genome, the CSF, or the blood, 
since there have been rapid developments in this arena; moreover, 
the laboratory assays for these biomarkers are relatively inexpen-
sive (compared to neuroimaging modalities). At the close of this 
review, we will also discuss longitudinal studies utilizing these 
biomarkers, individually and in combination, to better evaluate 
which of these may be clinically useful as long-term markers of 
AD progression.
GeNeTiC BiOMARKeRS
Several researchers have investigated the genetic makeup of those 
afflicted with Alzheimer’s compared to neurologically healthy 
individuals. Amyloid-β precursor protein (AβPP), presenilin 1 
(PSEN1), and presenilin 2 (PSEN2) genes have been strongly 
implicated in early onset Alzheimer’s disease (EOAD), particu-
larly familial EOAD, which comprise less than 5% of Alzheimer’s 
cases (15). In contrast, late onset Alzheimer’s disease (LOAD) 
has been associated with other genes including apolipoprotein 
E-ε4 (APOE ε4), bridging integrator 1 (BIN1) region, clusterin 
(CLU), phosphatidylinositol clathrin assembly lymphoid-myeloid 
(PICALM), and complement receptor 1, mostly identified through 
genome-wide association studies (GWAS) (http://www.alzgene.
org/). Among these most highly associated genes for LOAD, the 
APOE ε4 allele emerges as the most promising candidate. This 
relative rank of gene association to AD is based on the human 
genome epidemiology network interim criteria for the cumula-
tive assessment of genetic associations, which takes into account 
the sample size, heterogeneity across studies, and protection from 
bias within these studies.
Genetic tests are available for both APOE ε4 and the rare 
genes associated with EOAD. Traditionally, screening for AD 
associated genes via targeted sequencing methods, whether 
through Sanger or next-generation sequencing (NGS), was more 
commonly used than whole-exome sequencing due to lower costs 
and faster analysis (16). However, as the cost and running time 
of whole-exome sequencing has decreased, particularly through 
refined NGS methods, it has become a more widely used tool for 
genetic screening (17, 18). However, routine clinical testing for 
early detection is not currently recommended for most EOAD 
individuals since there is currently no effective treatment or pre-
vention for AD. Moreover, the identification of a mutation is not 
a certain predictor of disease or onset age, given that these muta-
tions can vary in terms of penetrance and gene expression (19). 
However, an increasing number of studies report the benefits of 
disclosing Alzheimer’s diagnosis early since it allows the patient 
to plan for their future with better access to good medical care and 
support services, as reviewed elsewhere (20). In fact, PSEN1 and 
PSEN2 testing is now recommended for individuals with early 
onset dementia who have at least one affected family member. 
PSEN2 testing is even further recommended for those individuals 
who also present with delusions or hallucinations (21). Likewise, 
AβPP testing is now recommended for individuals with early 
onset dementia who have at least one affected family member 
and in whom no PSEN1 mutation has been identified (21).
APOe ε4 ALLeLe
Among the many genes examined, the APOE ε4 allele emerges 
as the strongest genetic risk factor for AD (22). ApoE regulates 
lipid homeostasis by mediating lipid transport from one tissue 
or cell type to another. In the central nervous system (CNS), 
ApoE is produced mainly by astrocytes where they transport 
cholesterol to neurons via ApoE receptors (23). In humans, 
APOE polymorphism is represented by three different alleles: ε2, 
ε3, and ε4, which generally occur at frequencies of 8.4, 77.9, and 
13.7%, respectively, in Caucasian populations (24, 25). However, 
in those afflicted with AD, the frequencies are altered to 3.9, 
59.4, and 36.7% for the ε2, ε3, and ε4 alleles, respectively. These 
frequencies vary based on ethnic groups; whereas the Japanese 
population exhibits the highest, the Hispanic population exhibits 
the lowest frequency differences of the homozygous APOE ε4 
allele in AD patients versus healthy controls (24, 25). This differ-
ence in AD frequencies between ethnic groups is also reflected in 
their respective odds ratios (ORs) for AD: whereas the Japanese 
population exhibits the highest OR (33.1), the Hispanic popula-
tion exhibits the lowest (2.2) OR for the APOE ε4 homozygous 
genotype (Table 1).
TABLe 1 | Comparison of APOE ε4 allele as a marker for AD in various studies.
Reference Disease comparison  
(ethnic group)a
No. of cases 
(AD/non-AD)
APOE ε4 allele 
carrier type
Specificity  
(95% Ci)
Sensitivity  
(95% Ci)
PPv/NPv OR  
(95% Ci)
Farrer et al. (24) AD versus HC (Caucasian) (193/6,262) Homozygous N/A N/A N/A 12.5 (8.8–17.7)
AD versus HC (African American) (34/240) Homozygous N/A N/A N/A 5.7 (2.3–14.1)
AD versus HC (Hispanics) (12/267) Homozygous N/A N/A N/A 2.2 (0.7–6.7)
AD versus HC (Japanese) (45/1,977) Homozygous N/A N/A N/A 33.1 (13.6–80.5)
Saunders et al. (26) AD versus HC (46/10) Heterozygous 1 0.75 1.0/0.42 N/A
AD versus HC (11/10) Homozygous 1 0.19 1/0.18 N/A
Elias-Sonnenschein 
et al. (27)
AD versus MCI (35/35) Heterozygous 0.67 (0.62–0.71) 0.53 (0.46–0.61) 0.43/0.75 2.29 (1.88–2.80)
AD versus MCI (9/9) Homozygous 0.93 (0.90–0.97) 0.21 (0.10–0.33) 0.59/0.89 3.94 (2.09–7.33)
Vos et al. (28, 29) AD versus naMCI (73/226) N/A 0.62 (0.53–0.71) 0.56 (0.37–0.74) 0.25/0.86 1.8 (0.7–4.7)
AD versus aMCI (158/399) N/A 0.57 (0.49–0.64) 0.56 (0.46–0.66) 0.40/0.71 1.8 (1.1–3.0)
AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; APOE, apolipoprotein E; HC, healthy control; MCI, mild cognitive impairment; naMCI, non-amnestic mild 
cognitive impairment; OR, odds ratio; PPV/NPV, positive predictive value/negative predictive value.
aEthnic group included if only a particular group was studied.
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Corder et al. reported that the APOE ε4 allele increases the 
amount of amyloid deposition in a gene dose-dependent man-
ner, which was mirrored by their findings that AD frequency was 
increased among APOE ε4 homozygous individuals compared to 
those with only one APOE ε4 allele (91.3 versus 46.6%, respec-
tively) (30). Moreover, the mean age of clinical onset of AD was 
accelerated in APOE ε4 homozygous individuals compared to the 
heterozygotes (68 versus 76 years of age, respectively). For those 
lacking the APOE ε4 gene, AD frequency was found to be 20.4% 
with a mean onset age of 84 years. This increase in AD frequency 
among APOE ε4 homozygotes may be due to impaired delivery 
of cholesterol from astrocytes to neurons where increased choles-
terol concentration, especially those found in the membrane, may 
induce the accumulation of amyloid-beta1-42 (Aβ42) through the 
induction of the β-secretase pathway (31). In 1996, Saunders et al. 
sought to quantify the diagnostic value of the APOE ε4 allele in a 
real clinical setting (26). For both heterozygous and homozygous 
patients, they found that the positive predictive value (PPV) was 
100%, indicating that those who tested positive for the APOE ε4 
allele truly had AD. However, the negative predictive value (NPV) 
was low for both groups indicating that the absence of the allele 
does not necessarily prelude AD (Table 1).
In 2011, Elias-Sonnenschein et al. performed a meta-analysis 
to determine the predictive value of the APOE ε4 allele for pro-
gression from MCI to AD-type dementia (27). They extracted 
data from 35 studies involving a grand total of 1,236 AD patients. 
They found that the APOE ε4 allele was a moderately strong 
predictor of progression from MCI to AD-type dementia, with 
a PPV of 0.59 for APOE ε4 homozygotes. However, the PPV was 
considerably lower for the heterozygotes, and sensitivity was low 
for both groups (Table  1). These findings suggest that APOE 
ε4 may have limited utility in predicting disease progression in 
AD. Recently, Vos et  al. investigated whether potential genetic 
markers for AD were differentially distributed in patients with 
amnestic mild cognitive impairment (aMCI) versus those with 
non-amnestic mild cognitive impairment (naMCI) (28). They 
found that the APOE ε4 allele was similarly prevalent in naMCI 
and aMCI, at 40 and 47%, respectively. This contrasted with prior 
studies reporting that the absence of APOE ε4 allele was related to 
less memory impairment and should therefore occur at a much 
higher frequency in aMCI compared to naMCI (23). Similarly, 
the sensitivity and specificity of the APOE ε4 allele in predicting 
the development of AD from naMCI and aMCI were very similar 
(Table 1). This may have been due to the fact that they did not 
distinguish APOE ε4 allele carriers into homozygotes versus het-
erozygotes, and this becomes pertinent since the APOE ε4 allele 
behaves in a gene dose-dependent manner (25).
OTHeR POTeNTiAL GeNeTiC 
BiOMARKeRS
A couple of additional genetic markers have also been accorded 
relatively high ORs in the earlier GWAS studies (http://www.alz-
gene.org/), as well as a more recent meta-analysis (32), including 
BIN1, CLU, and PICALM. The BIN1 variant rs6733839 (OR of 
1.22; meta p-value of 6.9 × 10−44) (32) and an additional variant 
(rs59335482; an insertion of 3 cytosine bases) ~28 kb upstream 
of BIN1 have been associated with increased AD risk (OR of 
1.20; p-value of 3.8 ×  10−11) (33). BIN1 is a widely expressed 
adapter protein that functions in clathrin-mediated endocytosis 
and endocytic recycling, leading some researchers to believe 
that BIN1, in turn, functions in AβPP metabolism (34). BIN1 is 
also involved in the regulation of cytoskeleton dynamics, where 
the tubular membrane structures it forms appear to link the 
microtubule skeleton with the cellular membrane, leading others 
to believe that it modulates tau pathology (35, 36). PICALM is 
another widely expressed gene that encodes an adapter protein 
that functions in clathrin-mediated endocytosis and endocytic 
recycling, whose polymorphic variants rs3851179 and rs10792832 
have also been associated with AD in GWAS studies (32, 37, 
38). Although it is associated with similar functions as BIN1 
(i.e., clathrin-mediated endocytosis and endocytic recycling), it 
exhibits weaker association with LOAD (OR of 0.87; meta p-value 
of 9.3 × 10−26 for SNP rs10792832) (32). Although the exact role 
of PICALM in AD pathogenesis is unclear, PICALM has been 
implicated in APP processing and increased Aβ production in 
neurons (39).
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Clusterin, also known as apolipoprotein J, or CLU, is another 
gene significantly associated with LOAD, with an OR of 0.88 and 
a Bayes factor of 20.1 (http://www.alzgene.org/) and an OR of 
0.86 and a p-value of 2.8 × 10−25 (32). This molecule is abundantly 
expressed in neurons and astroglia, and tends to colocalize with 
Aβ, particularly in senile plaques (40). It has been suggested by 
several studies that CLU plays a protective role in AD patho-
genesis through the prevention of Aβ fibrillization, clearance of 
Aβ, inhibition of the complement system and neural apoptosis, 
and promotion of neurite growth (41–43). In particular, the 
rs11136000 and rs9331896 variants of CLU are associated with 
reduced AD frequency (OR of 0.89 and 0.86, respectively) (38). 
However, increased levels of CLU have been found in the CSF, 
frontal cortex, and hippocampus of AD patients. This apparent 
contradiction has led to the suggestion that some CLU AD-risk 
variant carriers may have an increased likelihood of developing 
AD later in life due to a diminished neuroprotective action of 
CLU, which may in turn lead to excessive production of CLU 
later in life (43). These findings are supported by a more recent 
study published in 2016 by Weinstein et al. suggesting that the 
association between plasma CLU levels and the risk of dementia 
may be dependent on age or an age-related factor (44). In this 
study, CLU was significantly associated with an increased risk of 
dementia among elderly subjects (>80 years of age; HR of 6.25) 
but reduced risk of dementia among younger subjects (<70 years 
of age; HR of 0.53).
Another genetic variant, only recently reported, also shows 
promise as a genetic marker of AD. Jonsson et al. analyzed the 
genomic sequences of 2,261 Icelanders and found rs75932628-T 
in triggering receptor expressed on myeloid cells 2 (TREM2) to be 
associated with a 2- to 4.5-fold increased risk of developing non-
familial AD (45). The OR was 2.26 for all population controls, 
2.92 for population controls 85 years of age or older, and 4.66 for 
cognitively intact controls (score of 0 on Cognitive Performance 
Scale) who were 85 years of age or older. The OR of rs75932628-T 
in the African American population was lower with a value of 
1.83, suggesting that the diagnostic value of this genetic variant 
may be ethnicity dependent (46). Additionally, another variant 
of TREM2, rs79011726, exhibited an OR of 2.14 in the African 
American population. TREM2 is an immune receptor that is 
found in brain microglial cells (47). Although the exact link 
between this genetic variant and AD pathogenesis is unclear, 
animal studies have indicated that microglia play an important 
role in how the brain responds to Aβ plaques (48).
Besides the above players, a few additional genes have also 
been uncovered through the more recent GWAS International 
Genomics of Alzheimer’s Project (IGAP) (32), including an 
association in the HLA-DRB5–DRB1 region (OR of 1.11; meta 
p-value of 2.9 × 10−12; SNP rs9271192). This region is involved 
in immunocompetence and histocompatibility and has already 
been shown to be a risk factor in multiple sclerosis (49). Since its 
discovery in 2013, one study has explored the role of HLA-DRB5, 
as well as 11 other newly discovered genetic risk factors (PTK2B, 
SORL1, SLC24A4, DSG2, INPP5D, MEF2C, NME8, ZCWPW1, 
CELF1, FERMT2, and CASS4), in AD pathogenesis. Recently, Yu 
et al. have reported that brain DNA methylation near HLA-DRB5 
was associated with pathological AD (p-value of 5.0 × 10−5) (50). 
Similar results have also been reported with some of the other 
novel genetic risk factors documented by IGAP, including SORL1 
and SLC24A4, and there will undoubtedly be more studies to 
come.
COMBiNeD GeNeTiC RiSK SCOReS 
(GRSs)
Recently, multiple studies have attempted to combine different 
genetic risk factors to determine whether a combined genetic 
panel could more accurately predict AD risk. In 2015, Adams et al. 
reported that there was a significant interaction between their 
AD GRS, containing 19 genetic variants, and the age-at-onset of 
dementia, whereby a stronger genetic effect was noted at earlier 
ages (51). This AD GRS included some of the genes mentioned 
above, such as APOE, PICALM, CLU, and BIN1. Adams et al. did 
not include mutations implicated in familial AD (PSEN1, PSEN2, 
and AβPP), since they wanted to focus on sporadic AD. They 
found that the novel AD-risk variants identified through GWAS 
were associated more closely with naMCI (OR 1.25), while 
APOE ε4 was better associated with aMCI (1.16) (51),. These 
results suggest that AD genes might influence different cognitive 
domains, but this appears to be in conflict with the 2013 study 
by Vos et al. particularly for APOE ε4, where Vos et al. reported 
that the APOE ε4 gene exhibited similar sensitivity and specificity 
when predicting the development of AD from naMCI and aMCI 
(Table 1). Nevertheless, Adams et  al.’s results are in agreement 
with prior studies that reported that the APOE ε4 gene occurs at 
higher frequencies in aMCI compared to naMCI (23). Though 
the association of the AD GRS to MCI and incident dementia is 
modest, the size of the study (N = 3,605) along with the continued 
follow-up of the initially non-demented subjects over 7–10 years 
raises hope that this GRS would be of utility in predicting disease 
development among cognitively normal individuals and that it 
may lead to a clinically useful test for AD. These findings also 
warrant a closer look at the effect of each individual genetic locus 
implicated in AD pathogenesis, particularly when preceded by 
MCI, a genetically heterogeneous condition.
In 2015, Sleegers et  al. also sought to study the predictive 
value of GRSs, which included several genes already discussed in 
this paper: APOE, PICALM, CLU, and BIN1 (52). Four different 
GRS models were created that are as follows: (1) ModelAPOE-S, 
(2) ModelAPOE-A, (3) ModelALL-WS, and (4) ModelALL-WA. The most 
promising and significant of these models was ModelALL-WA, which 
yielded a sensitivity of 55%, specificity of 78%, AUC of 0.70, and 
OR of 2.32 for discriminating AD patients, whether familial or spo-
radic, from healthy controls. ModelALL-WA was further analyzed for 
its discriminative ability between familial and sporadic AD. It was 
found to be a stronger predictor of familial AD (OR of 3.01 versus 
2.14). Logistic regression analysis of ModelALL-WA also showed an 
increased risk of AD with increasing risk score per unit increase 
in GRS [OR, 2.32 (95% CI, 2.08–2.58)], with this effect being 
more prominent in familial AD. Interestingly, the authors found 
no notable differences in the genetic risk profile in the presence 
or absence of APOE ε4 in their study population. Another recent 
study examined the interaction between PICALM and APOE and 
concluded that the PICALM genotype could modulate both brain 
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atrophy and cognitive performance in APOE ε4 carriers, and may 
perhaps be responsible for the absence of APOE ε4’s effect on the 
GRS reported by Sleegers et al. (53). Clearly, genetic interactions 
between the different genes implicated in AD and their functional 
consequences warrant further analysis.
CSF-DeRiveD NeUROCHeMiCAL 
BiOMARKeRS
Sampling CSF is a relatively non-invasive method for assessing 
pathologic alterations occurring within the CNS (9), although, 
some still consider the required lumbar puncture to be invasive, 
as there is a small risk of bleeding or brainstem herniation. Due 
to the CSF’s direct contact with the CNS, CSF-derived biomarkers 
have been studied extensively in AD (9, 54).
CSF Aβ PePTiDeS
It is well established that senile amyloid plaques, composed 
largely of Aβ peptides, accumulate in the cerebral cortex and 
hippocampus during the early stages of AD (54, 55). The prin-
cipal Aβ species deposited is Aβ42 as it is more hydrophobic and 
fibrillogenic. These aggregates of Aβ injure synapses, ultimately 
causing neurodegeneration and dementia (56). This accumula-
tion of Aβ42 within the cerebral cortex is hypothesized to be the 
result of overproduction of Aβ42 and/or reduced efflux of Aβ42 
across the blood–brain barrier into the CSF. Whatever the exact 
mechanism, the levels of Aβ42 within the CSF are decreased as a 
result (25). This decrease in baseline CSF levels serves as a poten-
tial basis for AD diagnosis. However, the exact baseline and cutoff 
value of CSF Aβ42 chosen for AD diagnostics has varied between 
different research group, hence yielding differing diagnostic 
performance metrics. Recent studies have begun to standardize 
their assay methods, resulting in more comparable results.
In 2003, Kapaki et  al. evaluated the diagnostic potential of 
CSF Aβ42 as a biomarker of AD (57). They particularly sought to 
differentiate AD from normal aging and other non-AD neuro-
degenerative dementias (NAND) within the Greek population. 
They found a 0.5-fold decrease in CSF Aβ42 levels in AD patients 
compared with normal aging, whose baseline level was 738 pg/
ml. In 2006, De Jong et al. found a similar fold difference of CSF 
Aβ42 basal levels in their AD group compared to healthy controls 
(58). The latter study attained a sensitivity of 0.93 compared 
to 0.82 in Kapaki et  al.’s study, which may be explained by the 
difference in CSF Aβ42 cutoff values used (490 versus 603  pg/
ml, respectively) or other patient-cohort specific differences. In 
2010, Mulder et al. carried out a similar analysis of CSF Aβ42 and 
achieved a diagnostic sensitivity and specificity in between that of 
Kapaki and De Jong et al. (59). This may also be related to the fact 
that their chosen cutoff value (550 pg/ml) was also in between the 
two earlier cutoff values (Table 2).
In a recent study reflecting the shift in Alzheimer’s biomarker 
research focus, Vos et al. did not seek to differentiate AD from 
healthy controls or NAND. Instead, they studied whether CSF 
Aβ42 could potentially predict if subjects with aMCI and naMCI 
would progress to AD (28). Recent studies have shown that AD 
pathology is common in subjects with naMCI; hence, Vos et al. 
investigated whether the diagnostic performance of this test 
would differ between these two types of MCI (61). With this CSF 
test, they were able to achieve slightly better diagnostic capability 
in predicting AD arising from aMCI compared to AD arising 
from naMCI, although the results were far from being optimal; 
these findings require independent validation. Although the same 
sandwich ELISA method (Innotest b-amyloid 1-42; Innogenetics, 
Ghent, Belgium) was used for CSF Aβ42 quantification in all of 
the above studies, there was variation in the CSF Aβ42 cutoff 
value used for diagnosis, and this may potentially account for the 
observed differences in diagnostic performance in the different 
studies. These results are summarized in Table 2.
Although CSF Aβ42 has been the most widely studied CSF Aβ 
peptide in AD, some studies have also investigated the biomarker 
potential of Aβ40, another component of the amyloid plaque that 
is primarily found in blood vessel walls (62). Gao et al. compared 
the diagnostic potential of the Aβ40 oligomer to that of the Aβ42 
monomer and found Aβ42 monomers to be superior (63). With a 
chosen cutoff value of 150 pg/ml (Aβ42 monomers are reduced in 
the CSF of AD patients), Aβ42 monomers exhibited a diagnostic 
accuracy of 88% compared to 83% for Aβ40 oligomers when delin-
eating between healthy controls and AD patients. An increasing 
number of studies have also found value in using the ratio of Aβ42 
to Aβ40 as an AD biomarker. In 2015, Dumurgier et al. investigated 
the diagnostic potential of Aβ42/Aβ40 ratio in a multicenter study 
(64). Overall, the Aβ42/Aβ40 ratio and isolated Aβ42 levels were 
found to have similar diagnostic accuracy in terms of discrimi-
nating AD from non-AD subjects with a sensitivity/specificity of 
0.73/0.78 and 0.78/0.79, respectively. Interestingly, the use of the 
Aβ42/Aβ40 ratio reduced the number of indeterminate CSF profiles 
by half and was in better agreement with the clinical diagnosis. 
These results raise the possibility that CSF Aβ42/Aβ40 ratios may 
better reflect brain amyloid production and warrant further 
investigation in longitudinal studies.
CSF TAU PROTeiN
Along with Aβ senile plaques, NFTs are also present within the 
hippocampus and cerebral cortex in the early stages of AD. These 
tangles are composed of filamentous hyperphosphorylated tau 
protein, whose total concentration is increased in the CSF of AD 
patients (10, 65). Total CSF tau levels have also been found to be 
increased in 90% of MCI patients who progressed to AD, imply-
ing that CSF tau protein may be a good biomarker for screening 
MCI patients who may eventually develop AD (65).
Kapaki et al. evaluated the diagnostic potential of total CSF 
tau protein as a biomarker of AD versus normal aging and other 
NAND within the Greek population (57). They observed a 3.5-
fold increase in CSF t-tau levels in AD patients compared with 
healthy controls, whose basal level was 140 pg/ml. In 2006, De 
Jong et al. found a similar fold difference of 3.3 for CSF t-tau levels 
in their AD group compared to healthy controls (58). Mulder 
et al., using a higher cutoff value for CSF tau than De Jong and 
Kapaki et al., obtained a lower specificity value of 0.78, although 
the sensitivity remained high at 0.85 (59). In the same 2013 study 
cited earlier, Vos et  al. also studied whether CSF t-tau protein 
TABLe 2 | Comparison of CSF biomarkers of AD in various studies.
Reference CSF biomarker Disease comparison No. of cases 
(AD/non-AD)
Threshold Specificity (95% Ci) Sensitivity (95% Ci) AUC PPv/NPv
Kapaki et al. (57) Aβ1-42 AD versus HC (49/49) 490 pg/ml 0.80 (0.66–0.90) 0.82 (0.68–0.91) 0.87 0.92/0.6
Aβ1-42 AD versus NAND (49/15) 435 pg/ml 0.80 (0.52–0.95) 0.71 (0.57–0.83) 0.76 0.84/0.65
De Jong et al. (58) Aβ1-42 AD versus HC (61/30) 603 pg/ml 0.93 0.93 N/A 0.97/0.88
Mulder et al. (59) Aβ1-42 ProbAD versus HC (131/248) 550 pg/ml 0.83 (0.76–0.89) 0.85 0.93 N/A
Vos et al. (28, 29) Aβ1-42 AD versus naMCI (39/226) 624 pg/ml 0.71 (0.57–0.85) 0.55 (0.33–0.77) N/A 0.48/0.76
Aβ1-42 AD versus aMCI (132/399) 550 pg/ml 0.58 (0.57–0.85) 0.75 (0.64–0.87) N/A 0.56/0.78
Kapaki et al. (57) Total tau AD versus HC (49/49) 317 pg/ml 0.96 (0.86–0.99) 0.88 (0.75–0.95) 0.95 0.98/0.73
Total tau AD versus NAND (49/15) 437 pg/ml 0.93 (0.68–0.99) 0.71 (0.57–0.83) 0.76 0.94/0.68
De Jong et al. (58) Total tau AD versus HC (61/30) 352 pg/ml 0.97 0.79 N/A 0.98/0.69
Mulder et al. (59) Total tau AD versus HC (131/248) 427 pg/ml 0.78 (0.65–0.91) 0.60 (0.39–0.81) N/A 0.57/0.80
Vos et al. (28, 29) Total tau AD versus naMCI (39/226) 427 pg/ml 0.78 (0.65–0.91) 0.60 (0.39–0.81) N/A 0.57/0.80
Total tau AD versus aMCI (132/399) 524 pg/ml 0.61 (0.50–0.72) 0.74 (0.62–0.85) N/A 0.57/0.77
Kapaki et al. (57) Aβ1-42/T-tau AD versus HC (49/49) 2.27 0.86 (0.73–0.94) 0.96 (0.86–0.99) 0.96 0.95/0.88
Aβ1-42/T-tau AD versus NAND (49/15) 1.06 1.0 (0.78–1.0) 0.71 (0.57–0.83) 0.92 1.00/0.70
De Jong et al. (58) Aβ1-42/T-tau AD versus HC (61/30) 1.895 0.95 0.97 N/A 0.98/0.91
Vos et al. (28, 29) Aβ1-42/T-tau AD versus naMCI (39/226) 0.96 0.54 (0.38–0.69) 0.90 (0.77–1.00) N/A 0.57/0.80
Aβ1-42/T-tau AD versus aMCI (132/399) 0.78 0.38 (0.27–0.48) 0.98 (0.94–1.00) N/A 0.57/0.77
Shaw et al. (60) Aβ1-42; T-tau 
with APOE ε4
AD versus NC (100/114) 0.34 0.80 0.98 0.94 0.86/0.97
Aβ42, amyloid-beta1-42 peptide; AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; HC, healthy control; MCI, mild cognitive impairment; naMCI, non-amnestic mild 
cognitive impairment; NAND, non-AD neurodegenerative dementias; PPV/NPV, positive predictive value/negative predictive value; T-tau, total tau; CSF, cerebrospinal fluid.
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could potentially predict if aMCI and naMCI would progress to 
AD (28) and found that CSF t-tau was equally predictive of AD 
development in both groups.
In addition to CSF t-tau, the main component of NFTs, CSF 
levels of phosphorylated tau (p-tau) have also been investigated 
as an AD biomarker. In 2006, De Jong et  al. investigated the 
diagnostic potential of p-tau for delineating AD patients and 
healthy controls. With a cutoff value of 68 pg/ml, p-tau yielded a 
sensitivity of 0.75, specificity of 0.85, and PPV/NPV of 0.93/0.55. 
p-tau did not reach the diagnostic value of t-tau in this study. 
Similar findings were reported by Mulder et  al. (59), where a 
cutoff value of 52 pg/ml for p-tau yielded a sensitivity of 0.85 and 
specificity of 0.68.
The same sandwich ELISA method (Innotest hTAU-Ag; 
Innogenetics, Ghent, Belgium) was used for all of the above 
studies investigating CSF t-tau and p-tau. Once again, there was 
variation in the chosen diagnostic test cutoff values in the differ-
ent studies, and this could potentially account for the reported 
differences in the sensitivity and specificity metrics reported in 
these studies. These results are summarized in Table 2.
CSF Aβ1-42/TOTAL TAU RATiOS
Interestingly, some of the above studies suggest that it is actually 
the ratio of these two CSF molecules that may serve as the ulti-
mate biomarker (28, 66), since combining CSF Aβ1-42 and t-tau 
increased the diagnostic accuracy compared to when they were 
used alone. This may reflect a physiological relationship between 
Aβ1-42 and t-tau that is particularly related to AD pathogenesis 
(67). At best, CSF Aβ1-42/total tau ratios attained specificity, 
sensitivity, and PPV values exceeding 95% in distinguishing AD 
from healthy control. The NPV of this ratio was about 90% in 
distinguishing AD from healthy controls and 70% in distinguish-
ing AD from disease controls (i.e., NAND) (Table 2).
CSF viSiNiN-LiKe-PROTeiN-1 (viLiP-1)
Visinin-like-protein-1 has been studied less extensively as a 
neurochemical biomarker compared to Aβ42 and tau protein. The 
family of visinin-like proteins, which are neuronal calcium sensor 
proteins, plays a role in both neuroprotective and neurotoxic func-
tions and have been implicated in a number of neurodegenerative 
diseases (68, 69). In particular, VILIP-1 has been identified as a 
marker of neuronal injury through GWAS and brain injury mod-
els where it is released into the CSF from injured neurons (70). 
Tarawneh et al. (71) have reported that CSF VILIP-1 levels differ 
between AD and normal cognitive subjects (520 versus 396 pg/
ml, respectively) and correlate with CSF t-tau, p-tau-181, and 
brain volumes in AD. CSF VILIP-1/Aβ42 ratios also differed sig-
nificantly between AD and normal cognitive subjects (1.55 versus 
0.74, respectively) and correlated with PiB-PET cortical binding 
potential, which is positively reflective of amyloid load. Clearly, 
further studies are warranted to compare the performance of this 
AD marker with previous biomarker candidates studied in the 
CSF. For reference, PiB-PET has been used in some studies in 
parallel with or to confirm CSF Aβ assay results since it is one of 
the leading neuroimaging tools with the potential to detect and 
provide quantitative measures of AD amyloid pathology in vivo 
at its early stages, with potential for longitudinal tracking (72, 73). 
The potential utility of imaging biomarkers in AD diagnostics 
have been reviewed recently (12, 14).
CSF YKL-40
Although markers associated with the underlying neuropathol-
ogy in AD, namely CSF Aβ and CSF tau, have remained the top 
candidates for AD diagnostics, these markers have also been 
found to be altered in other disorders such as dementia with Lewy 
bodies (DLB), frontotemporal dementia (FTD), and vascular 
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dementia (VAD). As a result, there has been a concerted effort 
to identify other biomarkers that can potentially distinguish 
these different neurological disorders from AD (74). In 2010, 
Craig-Schapiro reported elevated levels of CSF YKL-40 among 
very mild and mild-type AD dementia subjects using ELISA 
(75). YKL-40, also known as chitinase-3 like-1, is upregulated in 
various inflammatory conditions and expressed by different cell 
types such as activated neutrophils, macrophages, chondrocytes, 
and vascular smooth muscle cells (76). In the brain, it is mainly 
expressed by astrocytes. Further, in 2015, Wennström et  al. 
reported that CSF YKL-40 was elevated in AD subjects, but not in 
those with Parkinson’s disease or DLB, thus making it a potential 
distinguishing biomarker between these neurological disorders 
(77). Hellwig et al. found that YKL-40 had an AUC of 0.74 in dis-
tinguishing AD from non-AD subjects (78). However, Janelidze 
et al. reported no improvement in diagnostic accuracy of either 
prodromal AD or AD dementia when using YKL-40, compared 
to using core CSF AD biomarkers (Aβ and tau), although YKL-40 
was selectively increased in AD and FTD patients compared to 
the other dementias including DLB, VAD, and Parkinson’s disease 
dementia (79). There is no doubt that future studies will investi-
gate the diagnostic potential of YKL-40 further and confirm if 
YKL-40 is clinically useful in distinguishing between the different 
dementias.
CSF NeUROGRANiN (NGRN)
Another newly reported biomarker candidate is NGRN, a 
postsynaptic protein expressed mostly in the cortical areas of the 
brain suggesting a connection to cognition. It is concentrated 
in the dendritic spines of principal excitatory synapses, whose 
translocation thereof is impaired in AD; decreased NGRN levels 
have been observed in the hippocampus and cortex (80). In 2015, 
Kester et al. reported that CSF NGRN levels were higher in MCI 
and AD subjects, compared to cognitively normal subjects (81). 
This relationship persisted upon follow-up, 3.8 years later. It is 
believed that the increased levels of CSF NGRN may be second-
ary to their impaired translocation to dendritic spines. In the 
same study by Hellwig et  al. discussed above, CSF NGRN was 
found to have an AUC value of 0.85 when distinguishing AD 
from non-AD dementia subjects, suggesting that it may be more 
valuable diagnostically than YKL-40, and that it may also have 
the potential to distinguish different neuronal disorders, just like 
YKL-40 (78). In the same study by Janelidze discussed above, 
no improvement in diagnostic accuracy was noted in assessing 
prodromal AD or AD dementia when using CSF NGRN, com-
pared to using the core CSF AD biomarkers (79). The extent to 
which CSF NGRN, CSF YKL-40, CSF tau, CSF Aβ1-42, and other 
potential CSF proteins correlate with each other remains unclear. 
Clearly, this insight would be significant in constructing future 
diagnostic panels.
NGRN/BACe1 RATiO
Other studies have shown that combining CSF biomarkers have 
improved diagnostic performance, as that seen with CSF Aβ1-42/
tau ratios. In 2016, De Vos et al. investigated NGRN/BACE1 ratio 
as a potential AD biomarker and found that it correlated with 
yearly decline in mini-mental state examination (MMSE) scores 
in patients with MCI and dementia due to AD (β = −0.018 and 
−0.051, respectively) (82). β-site amyloid precursor protein cleav-
ing enzyme 1 (BACE1) is the β-secretase enzyme required for the 
production of the neurotoxic Aβ peptide and is thus considered 
to have a critical early role in the etiology of AD (83). Although 
extensive diagnostic values are lacking, this study showed this 
ratio’s potential as a prognostic biomarker and will undoubtedly 
be studied further for possible integration into clinical trials.
CSF Aβ1-42, TOTAL TAU wiTH APOE ε4
Combining both CSF proteins and genetic biomarkers in 2009, 
Shaw et al. developed a logistic regression model based on CSF 
Aβ42, t-tau, and the APOE ε4 allele (60). Logistic regression 
analyses were performed using sex, years of education, age 
at the time of lumbar puncture, APOE ε4 allele gene dosage 
(none, heterozygous, or homozygous), and each of the three 
CSF biomarkers: Aβ42, t-tau, and phosphorylated tau (p-tau-
181), with backward elimination and insertion into the model 
that had only Aβ42 and t-tau as variables, in order to identify 
optimal markers. With these multiple markers, they achieved a 
specificity of 79.5%, a sensitivity of 98.2%, an ROC AUC value of 
94.2%, and a PPV/NPV of 85.7/97.2% (Table 2). These sensitiv-
ity, NPV, and ROC AUC values were certainly among the highest 
reported, compared to the performance of the individual CSF 
biomarkers. However, the associated specificity was closer to the 
average specificities reported previously, where CSF t-tau, as a 
single biomarker, had a specificity of 96%. One potential sce-
nario could be to use the combined biomarker panel for initial 
screening (as it has high sensitivity) followed up by individual 
biomarker assays that have been shown to have higher specificity 
metrics.
BLOOD-DeRiveD BiOMARKeRS
In addition to studying CSF biomarkers, researchers have sought 
less invasive sources, such as blood (10, 84). Obtaining blood 
samples is relatively painless and inexpensive, giving potential 
blood-based biomarkers further advantage over the CSF-based 
markers. Some of the blood biomarkers appear to be just as 
diagnostically accurate as the CSF-based and genetic biomarkers 
though further validation is warranted. The major blood-derived 
biomarkers for AD discussed here have been identified through 
proteomic, lipidomic, and genomic profiling.
DiSCOveRY-BASeD PLASMA PROTeiN 
PANeLS
Ray et al. investigated biomarkers that could predict the progres-
sion of MCI to AD so that early preventative treatment can be 
delivered to AD-presymptomatic patients (85, 86). Using a 
filter-based, arrayed sandwich ELISA analysis of plasma from 
presymptomatic to late state AD and non-demented controls, they 
were able to identify a large number of elevated proteins within 
TABLe 3 | Comparison of blood biomarkers of AD in various studies.
Reference Blood biomarker Disease 
comparison
No. of 
cases (AD/
non-AD)
Accuracy Specificity 
(95% Ci)
Sensitivity 
(95% Ci)
AUC PPv/NPv
Ray et al. (86) 18-protein panel AD versus MCI (22/17) 0.90 N/A N/A N/A N/A
Hye et al. (87) 10-protein panel with APOE ε4 AD versus MCI (476/220) 0.87 0.88 0.85 0.84 0.69/0.95
Kiddle et al. (88) Covariatesa AD versus HC (80/53) 0.71 0.74 0.70 N/A 0.89/0.45
Replicated proteins with 
covariatesa
AD versus HC (80/53) 0.77 0.72 0.80 N/A 0.83/0.68
Mapstone et al. 
(89)
10 metabolite panel aMCI/AD versus HC (21/20) N/A N/A N/A 0.77 N/A
10 metabolite panel Converterspre versus 
HC
(10/20) N/A 0.90 0.90 0.92 N/A
Leidinger et al. 
(90)
12-miRNA signature AD versus HC (48/22) 0.933 ± 0.046 
(0.924–0.942)
0.951 ± 0.054 
(0.941–0.962)
0.915 ± 0.058 
(0.904–0.927)
N/A 0.949/0.918
12-miRNA signature AD versus MCI (94/18) 0.756 ± 0.078 
(0.741–0.772)
0.767 ± 0.083 
(0.751–0.784)
0.746 ± 0.097 
(0.727–0.765)
N/A 0.779/0.724
Bhatnagar et al. 
(91)
miRNA-34c AD versus HC (25/27) 0.94 0.96 0.92 0.99 0.958/0.923
Cheng et al. (92) 16 miRNA signatures with 
APOE ε4 
AD versus HC (16/36) N/A 0.77 0.87 N/A N/A
AD, Alzheimer’s disease; aMCI, amnestic mild cognitive impairment; APOE, apolipoprotein E; Converterspre, phenoconverters prior to conversion; HC, healthy control; MCI, mild 
cognitive impairment; naMCI, non-amnestic mild cognitive impairment; NAND, non-AD neurodegenerative dementias; PPV/NPV, positive predictive value/negative predictive value; 
miRNA, microRNA.
aThe covariates examined included age at disease onset, gender, and presence of APOE ε4 allele.
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these subjects. Using predictive analysis of microarrays, Ray et al. 
further narrowed down potential candidates to a predictor panel 
of 18 proteins (86). With this 18-protein panel, they were able 
to achieve a diagnostic accuracy of 90% in distinguishing AD 
and MCI subjects, where 81% of MCI subjects were accurately 
identified to progress to AD after a 2- to 6-year follow-up period 
(Table 3). They were classified with 90% positive agreement for 
the AD samples and 88% negative agreement for the non-AD 
samples. Although published in 2007, these proteins have not 
been replicated widely, while one study has reported no difference 
in a majority of these 18 proteins between AD and healthy sub-
jects (85). In 2014, in an independent study, Hye et al. achieved a 
high diagnostic accuracy with a 10-protein panel (87). Of these 
proteins, ICAM-1 was the only protein that overlapped with Ray 
et al.’s 18-protein panel.
In their 2006 study, Hye et al. performed proteomic analysis 
of plasma samples from AD and healthy elderly subjects using 
isoelectric focusing followed by polyacrylamide gel electropho-
resis (93). A set of 15 proteins was identified and validated using 
western blotting. For diagnostic analysis, the profile of these 
15 proteins in AD and healthy elderly subjects were measured 
using 2-D gel electrophoresis (2-DGE). Further support vector 
machine analysis of the 2-DGE data yielded a sensitivity of 56% 
and specificity of 80% for AD diagnosis (93).
In a later study, they analyzed plasma samples from AD, MCI, 
and elderly non-demented subjects using multiplex bead assays 
(Luminex xMAP) incorporated in 7 MILLIPLIEX MAP panels 
(87). In particular, Hye et  al. focused on 26 proteins that had 
been previously identified as potential AD biomarkers. These 
biomarkers include proteins from their earlier study in 2006 
[ceruloplasmin, complement factor H (CFH), and serum amyloid 
P-component precursor (SAP)] and proteins from the 18-protein 
panel reported by Ray et al. (93). Out of the 26 plasma proteins 
tested, Hye et al. found only 2 proteins, ApoE and CFH, to be 
significantly different between AD and controls.
In this same study, Hye et al. then proceeded to identify plasma 
proteins that could predict the progression of MCI to AD, which 
was assessed based on the degree of hippocampal atrophy. Using 
multivariate linear regression analysis, they identified six proteins 
that predicted 19.5% of hippocampal volume loss in subjects 
with MCI: CLU, neuron-specific enolase (NSE), TTR, vascular 
adhesion molecule 1, and SAP. In addition, seven proteins were 
identified that predicted 11.9% of hippocampal volume loss in 
subjects with AD: APOA1, alpha-1 antitrypsin (A1AT), ApoC3, 
brain-derived neurotrophic factor, AB40, plasminogen activator 
inhibitor-1, and NSE. They reasoned that since these proteins 
reflected pathological load, they might also predict conversion 
from pre-disease states (i.e., MCI) to clinical dementia (i.e., AD). 
Applying the Naïve Bayes simple machine learning approach 
to a test set, they found that the average time of conversion of 
MCI to AD was approximately 1  year where a combination of 
10 plasma proteins (TTR, CLU, cystatin C, A1AcidG, ICAM-1, 
CC4, pigment epithelium-derived factor, A1AT, RANTES, and 
ApoC3) coupled with the APOE ε4 genotype yielded the greatest 
predictive potential with 85% sensitivity, 88% specificity, 0.87% 
accuracy, and 68.8/95% PPV/NPV (Table 3). This protein panel 
did not quite reach the 90% diagnostic accuracy reported in Ray 
et al.’s study, but one can certainly envision further fine tuning of 
these protein panels to attain better diagnostic performance in 
future studies.
PROTeiN PANeL COMBiNeD wiTH  
APOE ε4 ALLeLe
In 2014, Kiddle et  al. reviewed 21 discovery or panel-based 
proteomic studies aimed at identifying protein biomarkers in 
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AD. Four of these markers (α-1 antitrypsin, α-2-macroglobulin, 
APOE, and complement C3) were replicated in 5 of the 21 inde-
pendent studies despite the use of different methodologies (88). 
Certain covariates, such as the age of disease onset and gender, 
coupled with the presence of APOE ε4 allele had some predic-
tive capability (Table 3). Combining these covariates with these 
four most highly replicated blood protein biomarkers improved 
the predictive potential (Table  3). These results indicate that 
combining biomarker leads from multiple OMICs approaches 
(e.g., proteomics and genomics) may lead to AD biomarkers with 
improved predictive performance. The biomarkers used in these 
studies also represent the molecules that have been validated in 
the largest numbers of independent patient cohorts.
DiSCOveRY-BASeD BLOOD LiPiD 
PANeLS
Recently Mapstone et  al. reported a set of 10 phospholipids 
from peripheral blood that predicted phenoconversion to 
either aMCI or AD within 2–3  years, with over 90% accuracy 
(89). These researchers performed an untargeted metabolomic 
analysis of 124 plasma samples from aMCI/AD (including post-
phenoconverters) that were taken at the start of the study, and 
3 years later. They then used tandem mass spectrometry to iden-
tify 10 metabolites that constituted a discriminatory signature: 
phosphatidylcholines (PCs) [PC diacyl (aa) C36:6, PC aa C38:0, 
PC aa C38:6, PC aa C40:1, PC aa, C40:2, PC aa C40:6, PC acyl–
alkyl (ae) C40:6], lysophosphatidylcholine (lysoPC a C18:2), and 
acylcarnitines (ACs) [propionyl AC (C3) and C16:1-OH]. These 
10 lipids were reduced in the plasma of the Converterpre group 
compared to the healthy controls, and they remained so even after 
phenoconversion to aMCI/AD (Converterspost) (Table  3). This 
10-lipid panel still needs to be validated in independent studies. 
Also, the biological relevance of these lipids to the pathogenesis 
of AD warrants careful evaluation.
DiSCOveRY-BASeD BLOOD microRNA 
(miRNA) SiGNATUReS
Several groups have attempted to identify potential miRNA 
signatures for AD (94, 95). One of the highest diagnostic accura-
cies among these studies was reported by Leidinger et al., who 
identified a panel of 12 miRNAs through NGS of blood miRNA 
transcriptomes from AD patients, MCI patients, and healthy con-
trols (90). This 12-miRNA signature was validated by RT-qPCR 
in a group of 202 patients suffering from other neurological 
disorders, which included MCI. While some blood miRNA were 
reduced in AD (hsa-let-7f-5p, hsa-miR-1285-5p, hsa-miR-107, 
hsa-miR-103a-3p, hsa-miR-26b-Sp, hsa-miR-26a-Sp, and hsa-
miR-532-Sp), others were elevated (hsa-miR-151a-3p, brain-
mir-161, hsa-let-7d-3p, brain-miR-112, and hsa-miR-5010-3p), 
when compared to the healthy controls. Leidinger et  al. were 
able to differentiate between AD and controls with an accuracy 
of 93%, a specificity of 95%, and a sensitivity of 92%, while the 
differentiation of AD from other neurological diseases (MCI, 
Parkinson’s disease, multiple sclerosis, and major depression) 
attained accuracies between 74 and 78% (Table  3). Though 
these results are promising, further independent validation is 
warranted.
In 2014, Bhatnagar et  al. reported that miRNA-34c is more 
highly expressed in the plasma (0.29 versus 0.1) and peripheral 
blood mononuclear cells (0.08 versus 0.07) of AD patients com-
pared to healthy controls (91). They then analyzed whether blood 
miRNA-34c could distinguish AD subjects from age-matched 
healthy counterparts. They achieved relatively high diagnostic 
accuracies, compared to other AD miRNA biomarker stud-
ies, with a sensitivity of 0.92, a specificity of 0.96, and a PPV/
NPV of 0.958/0.923. Validation in independent cohorts and 
comparison to other neurological disease controls are warranted. 
Interestingly, earlier studies have shown that miRNA-34c plays a 
role in the repression of genes involved in cell survival/apoptosis 
and neuroprotective signaling (96, 97).
miRNA SiGNATURe COMBiNeD wiTH 
APOE ε4 ALLeLe
In 2014, Cheng et al. identified a set of 16 miRNAs in the plasma 
of AD that could serve as a potential disease signature (92). This 
16 miRNA signature was created using NGS with qRT-PCR 
validation, a method used previously by Leidinger et al., though, 
there was no overlap between the miRNA signatures uncovered 
in these two studies (90). While some miRNA were reduced in 
AD (hsa-miR-1306-5p, hsa-miR-342-3p, and 15b-3p), others 
were elevated (hsa-miR-361-5p, hsa-miR-30e-5p, hsa-miR-93-5p, 
hsa-miR-15a-5p, hsa-miR-143-3p, hsa-miR-335-5p, hsa-miR-
106b-5p, hsa-miR-101-3p, hsa-miR-424-5p, hsa-miR-106a-5p, 
hsa-miR-18b-5p, hsa-miR-3065-5p, hsa-miR-20a-5p, and hsa-
miR-582-5p), when compared to the healthy control subjects. 
Combining this deregulated 16 miRNA signature with the pres-
ence of the APOE ε4 allele, Cheng et al. were able to discriminate 
AD subjects from healthy subjects with 77% specificity and 87% 
sensitivity (Table 3). The diagnostic parameters of this study may 
be less optimal than that of Leidinger et al. (77% specificity and 
87% sensitivity versus 95% specificity and 92% sensitivity, respec-
tively), even with the integration of the APOE ε4 allele, possibly 
due to a smaller cohort size (n = 60 versus n = 202, respectively). 
All of the above miRNA studies warrant independent validation 
and analysis in longitudinal data sets so as to identify common, 
reproducible themes. This becomes particularly pertinent given 
that there was no overlap between the findings of these two 
reports.
PLASMA Aβ1-42/Aβ1-40 RATiOS
Several studies have examined the predictive ability of plasma 
Aβ levels. This is not surprising given that CSF Aβ levels and 
Aβ accumulation, as determined by PiB-PET, are validated AD 
biomarkers (5, 7, 8, 29, 98). However, recent findings on the 
relationship between AD pathogenesis and plasma Aβ levels have 
been contradictory. Whereas some argue that an increase in the 
plasma Aβ42/Aβ40 ratio is related to an increased risk of developing 
AD (99), others report that it is actually the reduction of plasma 
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Aβ42/Aβ40 ratio that increases risk (72, 100–102). Interestingly, 
positron emission tomography (PET) measures of brain amyloid 
burden does show an association between reduced plasma Aβ42/
Aβ40 and increased brain amyloid load (72, 102). In addition, a 
recent study by Chouraki et al., examining the levels of plasma Aβ42 
and Aβ40 in 2,189 dementia-free individuals over an 8-year period, 
found that lower levels of plasma Aβ42/Aβ40 ratio were associated 
with an increased risk of developing dementia or incident AD 
(100). Likewise, Fei et al. followed the plasma Aβ42/Aβ40 ratios of 
588 subjects with MCI over 4–6 years to ascertain if these ratios 
can be used to identify those who may convert to AD. Fei et al. 
reported that plasma Aβ42/Aβ40 ratios exhibited a sensitivity of 
85.7% and specificity of 69.7% in this respect (103). Although the 
diagnostic value of plasma Aβ42/Aβ40 ratios did not quite surpass 
that of CSF Aβ42 used alone, these results call for further investiga-
tion of plasma biomarkers that may be reflective of amyloid load.
BLOOD BiOMARKeRS OF NeOCORTiCAL 
AMYLOiD BURDeN (NAB) iN AD
Along the same vein, researchers have searched for other blood-
based biomarkers that may reflect NAB, a pathophysiology 
known to increase the risk of AD (7, 104, 105). With these par-
ticular NAB biomarkers, researchers hope to identify an optimal 
window of treatment with anti-Aβ therapies (106). Very recently, 
Ashton et  al. reported that a single blood protein, fibrinogen 
γ-chain (FGG), selected from 17 discovery candidates, predicted 
high NAB when combined with age, yielding a sensitivity of 59% 
and specificity of 78%. High NAB was considered for standard-
ized uptake value ratios (SUVR) greater than 1.3 in PiB-PET 
scans, a cutoff value supported by previous studies (105). Other 
studies argue that an SUVR greater than 1.5 is a more appropriate 
cut off, but whether this difference has a significant impact on 
diagnostic performance is yet to be determined (107). Whereas 
plasma Aβ42/Aβ40 ratios exhibit moderately high sensitivity and 
moderately low specificity, FGG exhibits the inverse diagnostic 
relationship (104).
Voyle et al. also noted the promise of FGG. Very recently, they 
constructed a 5-metabolic feature panel, further enriched by the 
addition of FGG, to identify those with high NAB. These 5-meta-
bolic features were selected from an initial number of 3,196, after 
rigorous metabolomic analysis using multiple metabolic feature 
models (108). However, only four of the five metabolites, phos-
phatidylcholine (PCaa 36:6), PE 39:7, anandamide, and ananda-
mide isotope, were putatively identified. When combined with 
FGG, this 4-plex metabolic panel identified high-NAB subjects 
with a sensitivity of 71%, specificity of 84%, and accuracy of 79%, 
diagnostic values that exceed that of previously reported blood-
based biomarker for NAB. Collectively, these studies indicate that 
researchers are close to identifying blood-based biomarkers of 
NAB with accuracies approaching 80%.
LONGiTUDiNAL STUDieS
Recent studies have shown that approximately 30% of age-
matched HC individuals have preclinical AD based on two 
currently validated biomarkers, Aβ in PiB-PET measurements 
or Aβ in the CSF (6, 8, 98). This frequency does differ between 
reports, likely due to methodological differences between studies 
(109). These results and results from other clinicopathological and 
biomarker studies support the existence of a long preclinical stage 
during which AD pathologies develop, preceding the appearance 
of cognitive symptoms. Because of this, the primary focus of 
Alzheimer’s research has shifted from differentiation between HC 
and AD to determining the rates of cognitive decline in subjects 
who have preclinical, prodromal, or clinical AD. Through longi-
tudinal studies, researchers envision that an effective treatment 
window may emerge, which could potentially permit therapeutic 
intervention, including anti-Aβ therapies (106).
BASeLiNe CSF BiOMARKeRS veRSUS 
LONG-TeRM COGNiTive DeCLiNe
Based on their promising results in 2011, Tarawneh et al. examined 
the long-term prognostic potential of CSF VILIP-1 and VILIP-1/
Aβ42 ratios over a period of 2.6 years among AD patients (71, 110). 
CSF was only collected once at the beginning of the study and ana-
lyzed for t-tau, p-tau (or p-tau-181), Aβ42, and VILIP-1. To assess the 
progression of cognitive decline, 60 AD subjects were cognitively 
assessed using the clinical dementia rating sum of boxes (CDR-SB), 
annually, with an average of 3 cognitive assessments per subject. The 
CDR has high inter-rater reliability, is sensitive to clinical progres-
sion, and is highly predictive (93%) of autopsy-confirmed AD (111, 
112). Once AD diagnosis using CDR-SB was confirmed (using a cut 
off of 0.5), a psychometric test battery assessing a broad spectrum 
of cognitive functions was administered to all subjects. This test 
quantified the episodic memory composite, the semantic memory 
composite, the working memory composite, the visual spatial 
composite, and the global psychometric composite of all subjects.
Not surprisingly, higher basal levels of all the CSF biomark-
ers examined were associated with an increased rate of decline. 
However, CSF VILIP-1 and p-tau-181 proteins predicted the 
greatest decline (1.61 and 1.583, respectively) within the upper 
tercile group (with cut offs at 560 and 93  pg/ml, respectively), 
while in the lower tercile group, CSF VILIP-1 and t-tau protein 
predicted the greatest decline (0.852 and 0.828, respectively) of 
CDR-SB. For CSF VILIP-1/Aβ42 ratios, the rate of CDR-SB decline 
for both the upper and lower tercile group were the lowest among 
all the CSF biomarkers assessed, although still discernable. When 
analyzing the rate of decline for global psychometric and episodic 
memory composite scores, CSF VILIP-1/Aβ42 ranked highest 
(0.615 and 0.674, respectively), followed by CSF p-tau-181/Aβ42 
(0.594 and 0.659, respectively). This study’s conclusion that CSF 
VILIP-1 and CSF VILIP-1/Aβ42 ratio can predict global cogni-
tive changes resonates well with findings from other studies, as 
described below.
BASeLiNe DiSeASe STAGe veRSUS 
LONG-TeRM COGNiTive DeCLiNe
Vos et al. investigated the prevalence and long-term outcome of 
preclinical AD based on new classification criteria employing 
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preclinical disease stages, where stage 1 subjects were cognitively 
normal individuals with abnormal amyloid markers, stage 2 
subjects had abnormal amyloid and neuronal injury markers with 
no subtle cognitive changes, and stage 3 subjects had abnormal 
amyloid and neuronal injury markers with subtle cognitive 
changes (29). Three hundred eleven subjects underwent annual 
cognitive assessment, which included CDR and CDR-SB, MMSE, 
and a psychometric test battery. At the beginning of the study, all 
groups, including preclinical AD, were considered to have a CDR 
of 0, meaning that no dementia was present. Vos et  al. sought 
to map their progression to a CDR ≥ 0.5 (onset of symptomatic 
AD) over a 14-year period. CSF samples were obtained from all 
subjects and analyzed for t-tau, p-tau-181, and Aβ42 levels. APOE 
ε4 allele presence was also recorded, with stage 3 subjects hav-
ing the largest prevalence of APOE ε4 positivity (69%). Indeed, 
stage 3 subjects showed the highest rate of progression to clinical 
dementia (56% after 5  years), followed by stage 2 (26%), stage 
1 (11%), and the normal subjects (2%). This increased rate of 
progression to clinical dementia with increased preclinical 
stage score was also reflected by their progressively increasing 
deficits of CSF Aβ42 levels (355, 350, 321 pg/ml for stages 1, 2, 
and 3, respectively). These studies underscore the importance of 
factoring in baseline clinical symptoms, laboratory markers, and 
genotype in order to prognosticate future disease progression. 
Such a multi-pronged panel could also be of immense utility in 
tracking treatment response in future clinical trials.
CSF BiOMARKeR LeveLS veRSUS eOAD 
PROGReSSiON
In 2014, Fagan et  al. performed a longitudinal investigation of 
preclinical biomarkers based on clinicopathological evidence 
suggesting that the early pathological events of AD occur years 
before the onset of cognitive symptoms (8, 113). This study dif-
fered significantly from the other studies discussed above in that 
they studied subjects who were autosomal-dominant for AD and 
thus had EOAD in contrast to LOAD.
In their follow-up study, they enlisted a large cohort of 146 
mutation carriers (MCs) and 96 mutation non-carriers (NCs) 
from the dominantly inherited Alzheimer network, spanning a 
wide range of estimated number of years to symptom onset. They 
analyzed longitudinal CSF samples from a subset of 37 individu-
als (11 NCs and 26 MCs) examined every 5 years and found that 
in asymptomatic MCs, the serial change in CSF biomarkers was 
similar to those seen in previous cross-sectional LOAD studies, 
i.e., elevations in CSF t-tau, p-tau-181, and VILIP-1 and reduction 
in CSF Aβ42. The observation of CSF VILIP-1 elevations in MCs at 
least 15 years before their estimated age at symptom onset (EAO), 
with concentrations being even higher in individuals who were 
closer to their EAO, suggests a robust phase of neuronal injury 
and/or death that begins before the onset of cognitive symptoms. 
However, once the MCs reached their age of AD onset, Fagan 
et al. observed a decrease in CSF markers of neuronal injury/death 
(i.e., CSF t-tau, CSF p-tau-181, and VILIP-1) as time progressed. 
The rate of longitudinal change (adjusted for gender and APOE 
ε4 genotype) was documented as +6.90 to −10.79 pg/ml per year 
for CSF tau, 1.34 to −6.62 pg/ml per year for CSF p-tau-181, and 
−0.903 to −14.60 pg/ml per year for VILIP-1. This longitudinal 
evolution suggests that once these neuronal injury markers reach 
their peak release, which may occur during age at symptom onset, 
the rate of release of these markers may then slow down, in line 
with a progressive decline in neuronal injury/death. This study 
provides an impetus for further longitudinal studies of LOAD, 
with systematic serial monitoring of not only CSF markers, but 
also blood-derived biomarkers.
COMBiNeD GRS veRSUS RiSK OF 
CONveRSiON/RAPiD PROGReSSiON TO 
MCi
In 2013, Rodríguez-Rodríguez et al. evaluated whether a combined 
GRS, including APOE, BIN1, PICALM, and CLU, is associated 
with either risk of conversion or with rapid progression from MCI 
to AD (114). They followed 288 subjects with MCI over a mean 
period of 26.3 months and identified 118 MCI-converters to AD 
and 170 MCI-non-converters. Perhaps not surprisingly, APOE 
e4 was significantly associated with conversion risk (OR = 4.63) 
and rapid progression (HR 1.77), while CLU was associated with 
decreased conversion risk (OR 0.25), which is in agreement with 
previous studies suggesting that it has a neuroprotective role in 
AD pathogenesis (41). In contrast, Rodríguez-Rodríguez et  al. 
found no association between the combined GRS and the risk of 
conversion from MCI to AD. However, they did find that those 
who did convert and carried six risk alleles or more progressed 
about twice as quickly to AD than those who carried less than six 
risk alleles, with the acceleration of progression being an average 
of 5 months. This is somewhat of an improvement compared to 
using APOE e4 alone (HR 1.77). Unfortunately, the correlation 
between GRS (115, 116) and severity of AD development was not 
explored. Studies of this nature, which factor in multiple biomark-
ers, including the GRS, CSF, and blood-based biomarkers, will be 
useful for defining disease progression with better accuracy and 
possibly for designing interventional therapies.
CLiNiCAL TRiALS
There has been an increasing push to evaluate potential AD 
biomarkers not only for diagnostic accuracy in the preclinical 
stages of AD but also in their ability to serve as prognostic mark-
ers and theranostic markers of response to AD treatment (117). 
As mentioned previously, disease-modifying treatments are most 
likely to have maximal benefit during the preclinical stages of 
AD; hence, the focus of drug development has shifted from the 
dementia stage of the disease where previous treatment meth-
ods were found to yield only modest if any benefit (118, 119). 
Compared to the wealth of available biomarkers, very few of these 
have been factored into clinical trials. Where biomarkers have 
been utilized in clinical drug studies, they have served as inclu-
sion criteria for AD pathology presence and trackers of biological 
effects of treatment. Out of these studies, the bapineuzumab and 
solanezumab studies, which utilized PiB-PET and CSF biomark-
ers, initially showed promising results and progressed to phase III 
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trials, where they ultimately failed (115, 116, 120, 121). Despite 
these negative results, biomarkers are clearly valuable tools 
in clinical trials, as is becoming evident from lessons learned 
in other fields. The bottleneck is in deciding what the optimal 
biomarkers to use are. With this in mind, there has been a call 
for more longitudinal studies on biomarker trajectories, linking 
neuropathology to biomarkers, and discovering novel biomark-
ers reflecting other disease processes downstream of initial AD 
pathology (117). Undoubtedly, the use of the most promising 
CSF and blood biomarkers arising from these studies, alongside 
with concurrent neuroimaging biomarkers, is likely to play an 
increasingly important role in future clinical trials.
CONCLUSiON
A clinically useful biomarker should preferentially have a sensitiv-
ity, specificity, PPV, and NPV exceeding 90%. Using these criteria, 
several biomarkers discussed above, including CSF Aβ1-42/t-tau 
ratio (Table 2), 12-miRNA signature (Table 3), and miRNA-34c 
(Table  3), look promising as all of their diagnostic parameters 
exceed 90%. In addition, CSF Aβ42 and the blood-based 10 lipid 
test have both yielded reasonable sensitivity and specificity 
values, with Aβ42 alone yielding a PPV, at or greater than 90% 
(Tables 1 and 2, respectively). These biomarkers, particularly in 
combination, warrant further validation in multiple independent 
patient cohorts. Although initial results are promising, miRNA 
biomarkers in particular will need subsequent replication studies 
since this biomarker approach is newer. More importantly, efforts 
are warranted to mine newer biomarkers using more advanced 
screening platforms, including those that allow for global scans 
of proteins, peptides, and metabolites, in blood as well as CSF. 
With accelerated research, one is hopeful that improved, easily 
measurable biomarkers that can predict the rates of cognitive 
decline and NAB in subjects who have preclinical, prodromal, or 
clinical AD will emerge.
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